Evidence map›Paper›PMID 30109442›Full record

ArticleThe AAPS journal2018

Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules.

Marianne K Vormann, Linda Gijzen, Simon Hutter, Lisette Boot, Arnaud Nicolas, Angelique van den Heuvel, Jelle Vriend, Chee Ping Ng, Tom T G Nieskens, Vincent van Duinen and 8 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Marianne K VormannMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Linda GijzenMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Simon HutterMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Lisette BootMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Arnaud NicolasMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Angelique van den HeuvelMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Jelle VriendDepartment of Pharmacology and Toxicology, Radboud UMC, P.O. box 9101, 6500 HB, Nijmegen, the Netherlands.
Chee Ping NgMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Tom T G NieskensDepartment of Pharmacology and Toxicology, Radboud UMC, P.O. box 9101, 6500 HB, Nijmegen, the Netherlands.
Vincent van DuinenDivision of Analytical Biosciences, Leiden Academic Center for Drug Research, Einsteinweg 55, 2333CC, Leiden, the Netherlands.
Bjorn de WagenaarMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Rosalinde MasereeuwDivision Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, the Netherlands.
Laura Suter-DickSchool of Life Sciences, University of Applied Sciences Northwestern Switzerland, Gründenstrasse 40, 4132, Muttenz, Switzerland.
Sebastiaan J TrietschMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Martijn WilmerDepartment of Pharmacology and Toxicology, Radboud UMC, P.O. box 9101, 6500 HB, Nijmegen, the Netherlands.
Jos JooreMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Paul VultoMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands.
Henriette L LanzMIMETAS B.V, JH Oortweg 19, 2333 CH, Leiden, the Netherlands. h.lanz@mimetas.com.
Mimetas (Netherlands) · NLRadboud University Medical Center · NLCentre for Human Drug Research · NLFHNW University of Applied Sciences and Arts · CHRadboud University Nijmegen · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proximal tubules in the kidney play a crucial role in reabsorbing and eliminating substrates from the body into the urine, leading to high local concentrations of xenobiotics. This makes the proximal tubule a major target for drug toxicity that needs to be evaluated during the drug development process. Here, we describe an advanced in vitro model consisting of fully polarized renal proximal tubular epithelial cells cultured in a microfluidic system. Up to 40 leak-tight tubules were cultured on this platform that provides access to the basolateral as well as the apical side of the epithelial cells. Exposure to the nephrotoxicant cisplatin caused a dose-dependent disruption of the epithelial barrier, a decrease in viability, an increase in effluent LDH activity, and changes in expression of tight-junction marker zona-occludence 1, actin, and DNA-damage marker H2A.X, as detected by immunostaining. Activity and inhibition of the efflux pumps P-glycoprotein (P-gp) and multidrug resistance protein (MRP) were demonstrated using fluorescence-based transporter assays. In addition, the transepithelial transport function from the basolateral to the apical side of the proximal tubule was studied. The apparent permeability of the fluorescent P-gp substrate rhodamine 123 was decreased by 35% by co-incubation with cyclosporin A. Furthermore, the activity of the glucose transporter SGLT2 was demonstrated using the fluorescent glucose analog 6-NBDG which was sensitive to inhibition by phlorizin. Our results demonstrate that we developed a functional 3D perfused proximal tubule model with advanced renal epithelial characteristics that can be used for drug screening studies.

Indexed as

Cell Culture TechniquesPerfusionATP Binding Cassette Transporter, Subfamily B, Member 1Biological TransportCell LineCell PolarityCisplatinCyclosporineDose-Response Relationship, DrugEpithelial CellsHumansKidney DiseasesKidney Tubules, ProximalLab-On-A-Chip DevicesMembrane Transport ModulatorsMembrane Transport ProteinsATP Binding Cassette Transporter, Subfamily B, Member 1CisplatinCyclosporineMembrane Transport ModulatorsMembrane Transport ProteinsPhlorhizinSLC5A2 protein, humanSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorsapparent permeability (P app)kidney-on-a-chipnephrotoxicityproximal tubuletransepithelial transport

Identifiers

PMID30109442
OpenAlexW2885232549

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.